3 results
Approved WMOCompleted
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
Approved WMOCompleted
To estimate the efficacy of erlotinib administered as a single agent to chemo-naïve NSCLC patients as determined by the non progression rate (NPR) at 8 weeks.
Approved WMOPending
To date, no dedicated prospective, randomized, blinded trials have been performed to assess the benefit of CRT in patients with NICD. It is difficult to hypothesize whether CRT implantation may be beneficial in patients with NICD. The objective of…